Ben Adams

Insulet has sent out a voluntary medical device correction notice for a series of its Omnipod devices amid a manufacturing fault that could lead to insulin leaking and not being fully delivered.

PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare blood cancer drug Besremi to a much wider market.

Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called Human Life Foundation Models (HLFM) to help with its goal.

ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new, longer-acting medicines that can significantly reduce the risk of HIV

Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics.

British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analogue to “high definition.”

As Neurotech Pharmaceuticals looks to ramp up the launch of its first-ever commercial product, the biopharma is running a new video series to help boost awareness.

The pharma marketing world has unique insight into how words play into their world: Many months and many dollars are spent sculpting and perfecting the right word for a new drug, one that speaks to

Swiss medtech CeQur has raised $100 million in a new series E funding round for what it called its “most ambitious phase of commercial growth.”

As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.